News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Argenx Receives FDA Approval for VYVGART Hytrulo Prefilled Syringe for Self-Injection in gMG and CIDP
Friday, April 11, 2025Argenx SE a global immunology company focused on severe autoimmune conditions has received approval from the US Food and Drug Administration FDA for a new prefilled syringe version of VYVGART Hytrulo efgartigimod alfa and hyaluronidaseqvfc
Renovaro Completes Merger with BioSymetrics to Strengthen AI-Based Biomarker Discovery and Precision Medicine
Thursday, April 10, 2025Renovaro Biosciences Inc a TechBio company specialising in advanced diagnostics drug discovery and genetically enhanced cancer therapies has finalised its previously announced merger with BioSymetrics The transaction was completed on April
AmacaThera Forms Partnership with Global Pharmaceutical Company to Develop Long-Acting Biologic Using Hydrogel Platform
Wednesday, April 09, 2025AmacaThera a clinicalstage biotechnology company focused on drug delivery has entered into a new collaboration with a leading global pharmaceutical firm The partnership aims to develop a longacting singleinjection biologic using AmacaTheras proprieta...
DATROWAY® Gains EU Approval for Previously Treated Metastatic HR-Positive, HER2-Negative Breast Cancer
Tuesday, April 08, 2025DATROWAY datopotamab deruxtecan has received approval in the European Union EU for use in adults with unresectable or metastatic hormone receptor HR positive HER negative IHC IHC or IHC ISH breast cancer
Ethris and Lonza Partner to Develop Spray-Dried mRNA Vaccines for Respiratory Disease Prevention
Monday, April 07, 2025Ethris a biotechnology company focused on developing nextgeneration RNAbased treatments and vaccines has partnered with Lonza a global contract development and manufacturing organisation CDMO to create spraydried mRNA vaccine candidates
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Friday, April 04, 2025Enlivex Therapeutics Ltd a clinicalstage macrophage reprogramming immunotherapy company today announced that the first patient has been dosed in an investigatorinitiated Phase I trial to evaluate the safety tolerability and initial efficacy of Alloce...
Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome
Friday, April 04, 2025Minovia Therapeutics Ltd a clinical stage biopharmaceutical company advancing mitochondrial therapies for primary and secondary mitochondrial diseases today announced that the US Food and Drug Administration FDA has cleared its second Investigational...
Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis
Thursday, April 03, 2025Roche announced today that the Phase III MUSETTE trial comparing a high dose of OCREVUS ocrelizumab intravenous IV infusion to the currently approved OCREVUS IV mg dose in people with relapsing multiple sclerosis RMS did not meet its primary endpoin...
Amneal Introduces BORUZU™, a Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma
Wednesday, April 02, 2025Amneal Pharmaceuticals Inc a global biopharmaceutical company has introduced BORUZU a readytouse bortezomib injection in the United States Developed in collaboration with Shilpa Medicare Limited this oncology treatment is available for subcutaneous o...
IDEAYA Biosciences Secures US FDA Breakthrough Therapy Designation for Darovasertib in Neoadjuvant Uveal Melanoma
Tuesday, April 01, 2025IDEAYA Biosciences Inc a precision medicine oncology company focused on developing targeted therapeutics has received Breakthrough Therapy designation BTD from the US Food and Drug Administration FDA for darovasertib
